The results of this randomized, multi-center study appear in the first issue for December 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
PAH is a debilitating and potentially fatal disease characterized by the progressive narrowing of blood vessels in the lungs. In 2000, there were 163,000 hospital discharges in which one diagnosis was PAH. Although it is more common in women, ages 21 to 40, it can affect men or women at any age.
Vallerie V. McLaughlin, M.D., of the University of Michigan Medical Center, and nine associates studied 65 PAH patients who were being treated with bosentan, an endothelin receptor antagonist that helps to increase blood flow in the lungs.
The researchers gave 32 patients both bosentan and inhaled iloprost, a prostacyclin analog. The remaining patients received bosentan and a placebo.
Every patient who received the combined therapy increased their six-minute walk distance by more than 98 feet. In addition, 11 climbed from functional class III to class II on the New York Heart Association PAH classification list, which measures how severely patients are limited by their disease. None of the patients in the combined treatment group experienced clinical deterioration by the end of the 12-week study.
Bosentan is often used for initial therapy due to its ease of administration. However, for patients who remain impaired on single drug treatment, Dr. McLaughlin calls the addition of inhaled iloprost is a “potentially attractive clinical option.”
“During the 12-week study, time to clinical worsening was significantly longer in iloprost-treated patients than in placbo patients,” she continued. “None of the iloprost patients met the predefined criteria for clinical worsening, compared with five of the 33 placebo patients.”
The investigators found the drug combination to be both safe and effective. They noted that syncope, a brief loss of consciousness due to a temporary insufficient flow of blood to the brain, was infrequent with the combination therapy, which may be an effect of bosentan.
Since inhaled iloprost therapy requires administration approximately six times per day, the researchers acknowledged that some patients could find this regimen inconvenient and expensive, given the additional cost of combining drugs.
PAH has no known cause and is difficult to diagnose. Symptoms include shortness of breath following exercise, excessive fatigue, dizziness, fainting, and weakness, with symptoms tending to worsen over time.
Suzy Martin | EurekAlert!
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences